RPID RSI Chart
Last 7 days
3.8%
Last 30 days
-11.7%
Last 90 days
-14.4%
Trailing 12 Months
-9.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 23.1M | 0 | 0 | 0 |
2023 | 18.0M | 19.1M | 20.6M | 22.5M |
2022 | 22.4M | 20.1M | 18.0M | 17.1M |
2021 | 17.9M | 19.7M | 21.4M | 23.2M |
2020 | 0 | 0 | 0 | 16.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 11, 2024 | spignesi robert g. jr. | sold (taxes) | -10,126 | 0.981 | -10,323 | president and ceo |
Mar 11, 2024 | vezina victoria | sold (taxes) | -5,331 | 0.981 | -5,435 | chief human resources officer |
Mar 11, 2024 | wirtjes sean m | sold (taxes) | -7,312 | 0.981 | -7,454 | chief financial officer |
Mar 11, 2024 | wilson john j. addington | sold (taxes) | -9,387 | 0.981 | -9,569 | chief operating officer |
Feb 12, 2024 | wilson john j. addington | sold (taxes) | -5,576 | 0.96 | -5,809 | chief operating officer |
Feb 12, 2024 | spignesi robert g. jr. | sold (taxes) | -8,990 | 0.96 | -9,365 | president and ceo |
Feb 12, 2024 | vezina victoria | sold (taxes) | -2,617 | 0.96 | -2,727 | chief human resources officer |
Feb 12, 2024 | wirtjes sean m | sold (taxes) | -3,642 | 0.96 | -3,794 | chief financial officer |
Feb 06, 2024 | wilson john j. addington | acquired | - | - | 39,000 | chief operating officer |
Feb 06, 2024 | wirtjes sean m | acquired | - | - | 51,000 | chief financial officer |
Which funds bought or sold RPID recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | unchanged | - | 5,997 | 25,292 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -5.04 | 1,928 | 9,805 | -% |
May 15, 2024 | RESOURCES MANAGEMENT CORP /CT/ /ADV | reduced | -0.2 | - | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 492 | 71.00 | 81.00 | -% |
May 15, 2024 | ABG-WTT Global Life Science Capital Partners GP Ltd | unchanged | - | - | 768,339 | 1.85% |
May 15, 2024 | Bain Capital Life Sciences Investors, LLC | unchanged | - | 1,939,950 | 8,181,520 | 0.66% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -43.44 | -1,876 | 5,381 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 285 | 51,491 | 64,201 | -% |
May 15, 2024 | ADAGE CAPITAL PARTNERS GP, L.L.C. | sold off | -100 | -518,000 | - | -% |
May 15, 2024 | GLENVIEW CAPITAL MANAGEMENT, LLC | unchanged | - | 303,206 | 1,278,740 | 0.02% |
Unveiling Rapid Micro Biosystems, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Rapid Micro Biosystems, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.1M | 3.7M | -0.09 | 0.29 |
Rapid Micro Biosystems, Inc. News
Income Statement (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Revenue | -11.5% | 5,611,000 | 6,337,000 | 6,145,000 | 5,002,000 | 5,035,000 | 4,374,000 | 4,739,000 | 3,860,000 | 4,160,000 | 5,208,000 | 6,899,000 | 6,130,000 | 4,995,000 | 5,121,000 | 5,247,000 | 2,593,000 |
Costs and Expenses | 7.3% | 19,884,000 | 18,525,000 | 20,594,000 | 20,056,000 | 19,907,000 | 21,634,000 | 21,625,000 | 17,934,000 | 19,159,000 | 19,764,000 | 19,022,000 | 16,992,000 | 14,686,000 | - | 12,824,000 | 8,605,000 |
S&GA Expenses | 3.8% | 3,281,000 | 3,161,000 | 3,498,000 | 3,201,000 | 3,462,000 | 4,124,000 | 3,930,000 | 3,484,000 | 3,456,000 | 3,355,000 | 3,063,000 | 3,122,000 | 2,275,000 | - | 1,447,000 | 1,236,000 |
R&D Expenses | 15.8% | 3,842,000 | 3,318,000 | 3,116,000 | 3,233,000 | 3,153,000 | 3,403,000 | 2,973,000 | 2,965,000 | 3,525,000 | 2,855,500 | 2,441,000 | 2,337,000 | 2,147,000 | - | 2,224,000 | 1,244,000 |
EBITDA Margin | 2.5% | -2.63 | -2.70 | -2.97 | -3.21 | -3.47 | -3.71 | -3.71 | -3.39 | -2.95 | -3.13 | -1.49 | -1.63 | -1.79 | -1.99 | - | - |
Interest Expenses | -5.6% | 983,000 | 1,041,000 | 1,093,000 | 1,073,000 | 1,003,000 | 831,000 | 575,000 | 264,000 | 108,000 | -1,854,000 | -761,000 | 924,000 | 932,000 | - | 886,000 | 814,000 |
Income Taxes | -62.5% | 3,000 | 8,000 | 10,000 | 6,000 | 7,000 | 9,000 | 7,000 | -600,000 | 23,000 | 34,000 | 20,000 | 18,000 | 19,000 | - | 20,000 | 74,000 |
Earnings Before Taxes | - | - | - | - | - | - | - | - | -13,703,000 | -14,907,000 | -14,571,000 | -24,967,000 | -11,813,000 | -22,082,000 | - | -8,445,000 | -9,193,000 |
EBT Margin | 2.5% | -2.95 | -3.03 | -3.32 | -3.56 | -3.78 | -3.98 | -3.79 | -3.39 | -2.96 | -3.16 | -1.72 | -1.88 | -2.07 | -2.30 | - | - |
Net Income | -19.2% | -13,322,000 | -11,172,000 | -13,392,000 | -14,016,000 | -13,887,000 | -16,447,000 | -16,339,000 | -13,090,000 | -14,930,000 | -14,605,000 | -24,987,000 | -11,831,000 | -22,101,000 | -11,339,000 | -8,465,000 | -9,267,000 |
Net Income Margin | 3.5% | -2.25 | -2.33 | -2.81 | -3.17 | -3.32 | -3.55 | -3.28 | -3.36 | -2.96 | -3.16 | -3.28 | -2.73 | -2.86 | -2.31 | - | - |
Free Cashflow | -62.5% | -16,110,000 | -9,915,000 | -10,161,000 | -9,405,000 | -17,445,000 | -12,466,000 | -16,692,000 | -16,975,000 | -19,154,000 | -14,853,000 | -19,768,000 | -12,047,000 | -11,513,000 | - | - | - |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -11.0% | 128 | 143 | 150 | 161 | 173 | 191 | 202 | 216 | 230 | 241 | 254 | 129 | 70.00 |
Current Assets | -10.2% | 108 | 120 | 115 | 133 | 129 | 139 | 145 | 171 | 187 | 218 | 244 | 118 | 62.00 |
Cash Equivalents | -6.5% | 23.00 | 24.00 | 24.00 | 29.00 | 24.00 | 27.00 | 26.00 | 50.00 | 63.00 | 179 | 220 | 100 | 30.00 |
Inventory | 2.3% | 20.00 | 20.00 | 20.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 18.00 | 16.00 | 14.00 | 12.00 | 9.00 |
Net PPE | -1.7% | 13.00 | 13.00 | 13.00 | 13.00 | 14.00 | 14.00 | 13.00 | 13.00 | 12.00 | 11.00 | 9.00 | 7.00 | 7.00 |
Liabilities | -14.4% | 22.00 | 25.00 | 22.00 | 21.00 | 21.00 | 26.00 | 23.00 | 21.00 | 23.00 | 20.00 | 20.00 | 58.00 | 45.00 |
Current Liabilities | -17.8% | 16.00 | 19.00 | 16.00 | 14.00 | 14.00 | 19.00 | 15.00 | 13.00 | 15.00 | 18.00 | 18.00 | 16.00 | 16.00 |
Shareholder's Equity | -10.2% | 106 | 118 | 128 | 140 | 152 | 164 | 179 | 195 | 207 | 221 | 235 | - | - |
Retained Earnings | -3.1% | -441 | -428 | -417 | -403 | -389 | -375 | -359 | -343 | -330 | -315 | -300 | -275 | -241 |
Additional Paid-In Capital | 0.2% | 547 | 546 | 545 | 544 | 542 | 541 | 539 | 539 | 537 | 536 | 535 | 111 | 115 |
Shares Outstanding | 0.5% | 43.00 | 43.00 | 43.00 | 43.00 | 43.00 | 42.00 | 42.00 | 42.00 | 42.00 | 20.00 | 12.00 | 156 | - |
Float | - | - | - | - | 28.00 | - | - | - | 24.00 | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -63.5% | -15,525 | -9,497 | -9,708 | -9,190 | -16,686 | -11,655 | -15,105 | -14,986 | -16,801 | -12,887 | -19,309 | -11,506 | -11,262 | - | - | - |
Share Based Compensation | 6.2% | 1,085 | 1,022 | 1,251 | 1,234 | 1,243 | 1,105 | 673 | 1,258 | 983 | 678 | 584 | 390 | 191 | - | - | - |
Cashflow From Investing | 35.0% | 13,515 | 10,008 | 4,766 | 13,469 | 13,910 | 12,800 | -8,934 | 2,213 | -99,548 | -27,058 | -459 | 4,479 | 9,749 | - | - | - |
Cashflow From Financing | 1416.7% | 158 | -12.00 | 48.00 | -9.00 | 122 | 87.00 | 151 | -8.00 | 463 | -1,256 | 139,309 | -1,377 | 80,069 | - | - | - |
Condensed consolidated statements of operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue: | ||
Total revenue | $ 5,611 | $ 5,035 |
Costs and operating expenses: | ||
Research and development | 3,842 | 3,153 |
Sales and marketing | 3,281 | 3,462 |
General and administrative | 5,627 | 6,467 |
Total costs and operating expenses | 19,884 | 19,907 |
Loss from operations | (14,273) | (14,872) |
Other income (expense): | ||
Interest income, net | 983 | 1,003 |
Other expense, net | (29) | (11) |
Total other income, net | 954 | 992 |
Loss before income taxes | (13,319) | (13,880) |
Income tax expense | 3 | 7 |
Net loss | $ (13,322) | $ (13,887) |
Net loss per share - basic (in dollars per share) | $ (0.31) | $ (0.32) |
Net loss per share - diluted (in dollars per share) | $ (0.31) | $ (0.32) |
Weighted average common shares outstanding - basic (in shares) | 43,245,835 | 42,812,580 |
Weighted average common shares outstanding - diluted (in shares) | 43,245,835 | 42,812,580 |
Product | ||
Revenue: | ||
Total revenue | $ 3,713 | $ 3,324 |
Costs and operating expenses: | ||
Cost of revenue | 5,173 | 4,981 |
Service | ||
Revenue: | ||
Total revenue | 1,898 | 1,711 |
Costs and operating expenses: | ||
Cost of revenue | $ 1,961 | $ 1,844 |
Condensed consolidated balance sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 22,433 | $ 24,285 |
Short-term investments | 57,103 | 67,768 |
Accounts receivable | 4,921 | 5,532 |
Inventory | 20,418 | 19,961 |
Prepaid expenses and other current assets | 3,285 | 2,869 |
Total current assets | 108,160 | 120,415 |
Property and equipment, net | 12,615 | 12,832 |
Right-of-use assets, net | 5,988 | 6,240 |
Long-term investments | 0 | 2,911 |
Other long-term assets | 684 | 770 |
Restricted cash | 284 | 284 |
Total assets | 127,731 | 143,452 |
Current liabilities: | ||
Accounts payable | 1,164 | 1,973 |
Accrued expenses and other current liabilities | 7,049 | 9,907 |
Deferred revenue | 6,234 | 5,974 |
Lease liabilities, short-term | 1,153 | 1,132 |
Total current liabilities | 15,600 | 18,986 |
Lease liabilities, long-term | 5,916 | 6,214 |
Other long-term liabilities | 272 | 263 |
Total liabilities | 21,788 | 25,463 |
Commitments and contingencies (Note 14) | ||
Stockholders’ equity: | ||
Preferred stock, $0.01 par value: 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Additional paid-in capital | 547,300 | 546,051 |
Accumulated deficit | (441,707) | (428,385) |
Accumulated other comprehensive loss | (78) | (101) |
Total stockholders’ equity | 105,943 | 117,989 |
Total liabilities and stockholders’ equity | 127,731 | 143,452 |
Class A Common stock | ||
Stockholders’ equity: | ||
Common stock | 375 | 371 |
Class B Common stock | ||
Stockholders’ equity: | ||
Common stock | $ 53 | $ 53 |